Logo

Thermo Fisher Scientific: Garret Hampton

May 13, 2020

Garret Hampton has been appointed as president of the clinical next-generation sequencing and oncology business at Thermo Fisher Scientific. He joins the firm from Illumina, where he was senior VP of clinical genomics. Before that, he was VP and global head of oncology biomarker development and companion diagnostics at Genentech. Hampton holds a PhD in cancer genetics from the University of London and an undergraduate degree in natural sciences from Trinity College Dublin.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.